ABOUT US
We provide innovative gene editing reagents and screening services for the global R&D market. Our success is based on the proprietary 3Cs technology developed at Goethe University’s Institute of Biochemistry II (IBC2).
Vivlion is a spin-out of Goethe University Frankfurt am Main founded in December 2018 by a team of scientists together with Goethe University Frankfurt am Main as a shareholder. Seed funding was secured by a private equity company, gsccb Beteiligungsverwaltung GmbH.
Frank Junker
Chief Executive
Officer
Ivan Đikić
Co-Founder &
Advisory Chairman
Kerstin Koch
Co-Founder & Head Business Development
Seasoned life-science professional with more than 20 years experience as business leader.
Renowned biomedical scientist and professor of Goethe University Frankfurt.
Experienced project manager with background in life sciences and journalism.
Manuel Kaulich
Co-Founder &
Chief Technology Officer
Martin Wegner
Head of R&D and Customer Solutions
Soenke Baestlein
Chief Financial Officer
Lead inventor of 3Cs technology and professor at Goethe University Frankfurt.
Venture capital investor, former senior partner in consulting and private equity.
Bioinformatician and co-developer of 3Cs technology and computational pipelines.
Vivlion is advised by representatives of Goethe University Frankfurt am Main and its technology transfer company Innovectis GmbH.
CRISPR gRNA library libraries 3Cs CRISPR/Cas Vivlion GmbH pooled arrayed CRISPR/Cas reagents screens validated products single multiplex multiplexing fixed-pair predefined combinations combinatorial screening